[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group name:Arm 1 Type of group;1 N\u00b0 of participants:70 Intervention(s) description:Patients will receive Acalabrutinib 100 mg VO twice daily (BID) per 10 days plus the best supportive care during the time at the discretion of the investigator and institutional guidelines.\t\t\t\tGroup name:Arm 2 Type of group;2 N\u00b0 of participants:70 Intervention(s) description:Patients will receive only the best supportive care during the time at the discretion of the investigator and institutional guidelines.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 12, "treatment_name": "Acalabrutinib", "treatment_type": "Kinase inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group name:Arm 1 Type of group;1 N\u00b0 of participants:70 Intervention(s) description:Patients will receive Acalabrutinib 100 mg VO twice daily (BID) per 10 days plus the best supportive care during the time at the discretion of the investigator and institutional guidelines. Group name:Arm 2 Type of group;2 N\u00b0 of participants:70 Intervention(s) description:Patients will receive only the best supportive care during the time at the discretion of the investigator and institutional guidelines.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]